Molecular Targets for the Treatment of Histiocytosis
Molecular Targets for the Treatment of Histiocytosis
The primary objective: to develop technical and operating procedures for detection mutations
 of histiocytosis during clinical practice of no-specialized molecular platforms, for
 diagnosis and follow-up of the disease.

 The secondary objectives: to describe therapeutic target mutations in histiocytosis patients,
 and to develop the cellular tests to evaluate in vitro the sensibility of these mutations
 drive to inhibitors.
The study is ancillary of the French "Gene Histio" cohort (patients already included) and
 "HISTIO target 2020" cohort (patients recruited since may 2020).

 The data base of the French registry of histiocytoses is held by Dr J. Donadieu, and
 localized in Trousseau hospital (APHP) 75012 Paris, France, where server and backup are kept.
Inclusion Criteria:

 -  Histologically proven histiocytosis;

 -  Informed consent form signed by patients (or parents/legal tutors of children) to
 participate"Gene Histio" or "HISTIO target 2020".

 Exclusion Criteria:

 - Patient refusal.